Market Overview - The Hang Seng Index rose 1.74% and the Hang Seng Tech Index increased by 3.08% on the first trading day of May [1] - Despite a seemingly positive outlook for US stocks, there was a significant outflow of $8.9 billion from the US stock market, marking the largest outflow since December 2023 [1] - The US Chamber of Commerce urged the Trump administration to implement a tariff exemption mechanism to prevent economic recession and harm to small businesses [1] Trade Relations - The Chinese Ministry of Commerce noted a shift in the US stance regarding tariff negotiations, indicating a willingness to engage in talks [2] - The FTSE China A50 index futures reacted positively, rising over 0.9%, and the offshore RMB appreciated significantly against the USD [2] - New tariff adjustments confirmed that auto parts from Canada and Mexico will be exempt from a 25% tariff starting May 3 [2] Automotive Sector - Xpeng Motors reported a record delivery of over 30,000 vehicles for six consecutive months, with specific models achieving significant sales milestones [3] - Leap Motor's delivery volume for April reached 41,039 units, a 173% year-on-year increase, leading to a stock price increase of over 7% [3] - Xiaomi's automotive division also saw a rise in deliveries, contributing to a stock increase of over 6% [3] Technology Sector - Major US tech companies like Meta, Microsoft, and Apple reported strong earnings, unaffected by tariff issues, and reaffirmed aggressive AI investment plans [4] - The upcoming US non-farm payroll report is anticipated to influence market expectations regarding Federal Reserve interest rate decisions [4] - President Trump's recent sanctions on countries purchasing oil from Iran are viewed as a bargaining chip rather than a definitive policy change [4] Berkshire Hathaway - Berkshire Hathaway's annual shareholder meeting is set to take place, where Warren Buffett will discuss market perspectives and investment strategies, including significant cash reserves [5] Nuclear Energy Development - There is a global surge in the development of small modular reactors (SMRs) driven by climate change initiatives and demand for clean energy [6] - China's advancements in SMR technology are notable, with significant projects like the BEST project aimed at demonstrating fusion energy generation [6] Company Performance - China State Construction International reported a 5.5% year-on-year revenue increase in Q1 2025, with a notable rise in technology-related income [7] - The company’s new contract value decreased by 29.1% year-on-year, but adjusted figures show a strong performance when excluding high baseline effects from previous major projects [8] - The technology segment's revenue contribution increased to 20%, indicating a positive trend in the company's business model and market positioning [8]

Financial Performance - In 2024, the company achieved a revenue of CNY 12,275.8 million, representing a year-on-year growth of 6.4%[11] - The profit attributable to the owners of the parent company was CNY 1,793.4 million, reflecting a year-on-year increase of 12.0%[11] - The net cash flow from operating activities was CNY 2,576.7 million, a decrease of 6.4% compared to the previous year[11] - Total revenue for the year ended December 31, 2024, was approximately RMB 12,275.8 million, an increase of about RMB 737.8 million or 6.4% compared to 2023[17] - Profit attributable to equity holders of the parent company was approximately RMB 1,793.4 million, representing an increase of about 12.0% from the previous year[17] - Net cash flow from operating activities was approximately RMB 2,576.7 million, a decrease of about 6.4% compared to 2023[17] - The gross profit for 2024 was approximately RMB 4,149.3 million, reflecting a slight increase of 1.3% from 2023[17] - The company achieved operating revenue of 12,275.8 million, a year-on-year increase of 6.4%[36] - The net profit attributable to the parent company was 1,793.4 million, up 12.0% compared to the same period last year[36] Research and Development - The company participated in 781 global innovative drug discovery projects in 2024[12] - The company provided services for 1,066 drug molecules or intermediates, including 782 preclinical projects and 242 clinical I-II phase projects[12] - The company is currently conducting 1,062 clinical trial projects, including 94 phase III clinical trials[12] - In 2024, the company published 42 articles in international academic journals and obtained or submitted 34 domestic and international patents[12] - The company made significant advancements in automation and artificial intelligence technologies, enhancing drug development efficiency[13] - The company continues to strengthen its core competitive advantages in new drug research and development services[13] - The company aims to cultivate more skilled and dynamic talent through various academic platforms and awards to enhance its innovation capabilities[16] - The company is committed to leveraging AI technology for target discovery and drug evaluation, integrating multi-omics data to improve efficiency in drug discovery services[15] - The company is actively exploring AI and machine learning applications in drug discovery and process optimization to enhance R&D efficiency[42][48] - The company has established a comprehensive clinical trial service platform in China and an independent early clinical research center in Maryland, USA, with 96 beds[51] Service Capabilities - The company operates a leading integrated pharmaceutical R&D service platform with 21 R&D centers and production bases across China, the UK, and the US[25] - The laboratory services include drug chemistry, synthesis chemistry, and biological sciences, covering small molecule drugs, oligonucleotides, peptides, and antibody-drug conjugates[28] - The CMC (small molecule CDMO) services support clients in drug development stages, including process development and production for various products[30] - The clinical research services encompass overseas and domestic clinical trials, with a focus on early clinical trials and regulatory submissions[31] - The company has established bioanalytical platforms in China and the US to support global clinical trials for small molecules and biologics[32] - The company aims to enhance its international service capabilities to provide cross-disciplinary and cross-regional solutions for clients[25] - The company is committed to becoming a global leader in multi-therapy drug development services[25] - The company offers large molecule drug discovery and development services, including cell line development and production processes[33] - The company has established a leading integrated pharmaceutical R&D service platform, expanding its capabilities in small molecules, peptides, oligonucleotides, and gene therapy drugs, while maintaining a strong position in drug discovery and early clinical research[83] Environmental and Social Responsibility - The company reduced greenhouse gas emissions by 21% in 2024 compared to 2023, successfully achieving its annual carbon reduction target[40] - The company was included in the S&P Global "Sustainability Yearbook 2025" and improved its MSCI ESG rating to AA[40] Client Engagement and Market Position - The company served over 3,000 global customers in 2024, with revenue from customers using multiple service segments reaching 9,187.8 million, accounting for 74.8% of total revenue[37] - Revenue from the top 20 global pharmaceutical clients was 2,188.5 million, a year-on-year increase of 26.9%, representing 17.8% of total revenue[37] - The company has attracted over 900 new clients in 2024, with nearly 95% of its revenue coming from a loyal and diverse customer base[98] - The company emphasizes strategic partnerships with specific clients, enhancing its technical capabilities and service quality through shared proprietary knowledge and training[99] Governance and Management - The board consists of eight members, including three executive directors, two non-executive directors, and three independent non-executive directors, ensuring diverse governance[133] - The board has reviewed its diversity policy on March 26, 2025, and considers the current implementation effective[175] - The board's structure includes three executive directors, two non-executive directors, and three independent non-executive directors, ensuring a balanced governance approach[171] - The company emphasizes a culture of "employees first, customers at the center," which is integral to its operational strategy[164] - The board will continue to enhance communication with shareholders to improve governance standards and incorporate their reasonable suggestions[168] Financial Strategy and Investments - The company completed the sale of its stake in PROTEOLOGIX, INC. to Johnson & Johnson for approximately USD 102 million, receiving USD 86.195 million after adjustments[74] - The company has committed RMB 280 million as a limited partner in the Yongxin Kangjun Fund, which constitutes a related party transaction under the listing rules[77] - The company has signed a comprehensive strategic cooperation agreement with AstraZeneca Investment (China) Co., Ltd., focusing on integrated services for drug discovery, preclinical and clinical development, with an investment totaling RMB 191 million in the AstraZeneca Fund, accounting for 8.46% of the total subscription[76] Risks and Challenges - The company faces risks from fluctuations in the pharmaceutical investment climate and changes in R&D budgets from multinational pharmaceutical companies, which may impact growth expectations[113] - The company has established a strong talent pool but risks losing qualified research personnel to competitors, which could affect service quality[114] - Regulatory compliance is critical, as failure to meet standards could result in operational suspensions or penalties, impacting client relationships[116] - Foreign exchange risks are significant, with a large portion of revenue generated in USD while costs are primarily in RMB, leading to potential volatility[120] Future Outlook - The company aims to enhance its integrated drug R&D service platform, focusing on ADC and peptide services while strengthening its small molecule R&D capabilities[104] - The company plans to expand its customer base in large molecule and cell and gene therapy services, leveraging its existing advantages to improve operational efficiency[104] - The company is committed to a dual-market strategy, enhancing its presence in both domestic and international markets, with a focus on optimizing service platforms and attracting new clients[105] - The company will continue to develop its large molecule and cell gene therapy service platforms, leveraging existing laboratories in the US and UK[108]

Financial Performance - In Q1 2025, the Company reported revenue of RMB 2,671 million, a decrease of 16.0% compared to RMB 3,099 million in Q1 2024 [10] - Net profit for Q1 2025 was RMB 231 million, down 32.5% from RMB 306 million in Q1 2024 [10] - Non-IFRS net profit slightly decreased by 3.1% to RMB 339 million from RMB 349 million in Q1 2024 [10] - Net operating cash flow was RMB 746 million, a decline of 14.4% from RMB 853 million in Q1 2024 [10] Revenue Composition - Revenue from China entities accounted for 88%, while overseas subsidiaries contributed 12% [12] - Laboratory services generated 60% of total revenue, followed by small molecule CDMO services at 22%, and clinical development services at 14% [12] - Revenue from the top 20 pharmaceutical customers grew by 29.1%, while revenue from other customers increased by 14.0% [12] Growth Rates - New purchase orders (POs) achieved over 10% year-on-year growth in Q1 2025 [10] - Revenue from China entities grew by 15.7%, while overseas subsidiaries saw an 18.3% increase [12] - North America revenue increased by 16.8%, and EU revenue grew by 26.6% [12] Cost and Margin Analysis - Gross margin for laboratory services improved to 45.5% in Q1 2025 from 44.1% in Q1 2024, reflecting a 1.4 percentage point increase [14] - Gross margin for small molecule CDMO services rose to 30.4%, up 2.5 percentage points from 27.9% in Q1 2024 [15] - Clinical development services in China achieved a gross margin of 11.8%, an increase of 2.5 percentage points from 9.3% in Q1 2024 [16] Future Outlook - The Company maintains a revenue growth guidance of 10-15% for 2025 [27] - Despite macroeconomic uncertainties, the Company believes in sustained industry development driven by healthcare demands and technological innovations [27]

Financial Performance - Revenue for Q1 2025 reached RMB 3,099 million, a 16.0% increase from RMB 2,671 million in Q1 2024 [9] - Net profit attributable to shareholders was RMB 306 million, up 32.5% from RMB 231 million in Q1 2024 [9] - Non-IFRS adjusted net profit increased by 3.1% to RMB 349 million from RMB 339 million [9] - Operating cash flow for Q1 2025 was RMB 853 million, a 14.4% increase from RMB 746 million in Q1 2024 [9] Revenue Composition - Revenue from China delivery business grew by 15.7% [11] - Revenue from overseas delivery business increased by 18.3% [11] - Laboratory services contributed 60% to revenue, with clinical research services at 14% and CDMO at 22% [11] - Revenue from top 20 pharmaceutical companies grew by 29.1% [14] Customer Growth - Revenue from North American clients increased by 16.8% [12] - Revenue from European clients rose by 26.6% [12] - Revenue from Chinese clients grew by 13.1% [12] Cost and Margin Analysis - Gross margin for laboratory services improved to 45.5% in Q1 2025 from 44.1% in Q1 2024 [17] - Gross margin for clinical services increased to 11.8% from 9.3% [19] - Gross margin for large molecule services improved despite being in a construction phase [20] Strategic Outlook - The company aims for a revenue growth target of 10-15% for the full year 2025 [33] - The company emphasizes the importance of health demand and technological innovation in driving industry growth [33]

Core Viewpoint - 康龙化成 has shown strong growth in new orders and continues to enhance its global presence, leading to a positive outlook for the company [1][2]. Financial Performance - In Q1 2025, 康龙化成 achieved revenue of 30.99 billion yuan, a year-on-year increase of 16.03% - The net profit attributable to shareholders was 3.06 billion yuan, up 32.54% year-on-year, while the net profit excluding non-recurring items was 2.92 billion yuan, reflecting a 56.08% increase year-on-year [2]. - The gross margin for Q1 2025 was 66.34%, showing a year-on-year decrease of 1.01 percentage points but a quarter-on-quarter increase of 1.51 percentage points [2]. Business Segments - New orders increased by over 10% year-on-year, with laboratory services and CMC (small molecule CDMO) services both seeing significant growth [3]. - Revenue by segment includes: - Laboratory services: 18.57 billion yuan, up 15.74% year-on-year - CMC (small molecule CDMO) services: 6.93 billion yuan, up 19.05% year-on-year - Clinical research services: 4.47 billion yuan, up 14.25% year-on-year - Large molecule and cell & gene therapy services: 9.87 billion yuan, up 7.94% year-on-year [3]. Investment Outlook - The company is expected to generate revenues of 137.15 billion yuan, 155.39 billion yuan, and 173.88 billion yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 11.7%, 13.3%, and 11.9% [4]. - The net profit forecasts for the same years are 17.56 billion yuan, 21.77 billion yuan, and 24.71 billion yuan, with corresponding price-to-earnings ratios of 24, 19, and 17 [4].

Core Viewpoint - The company reported a slight revenue beat in Q1 2025, with adjusted Non-IFRS net profit slightly below expectations, primarily due to higher-than-expected losses from non-operating items [1] Revenue Performance - Q1 2025 revenue reached RMB 3.099 billion, representing a 16% year-over-year increase but a 10.4% quarter-over-quarter decline, slightly above expectations [1] - Laboratory services and clinical research services outperformed expectations, contributing to revenue growth [1][2] Segment Analysis - Laboratory services revenue grew by 15.7% YoY and 1.6% QoQ, with gross margin slightly improving by 1.4 percentage points YoY and 0.2 percentage points QoQ [2] - CMC services revenue increased by 19.1% YoY but decreased by 31.5% QoQ, with a gross margin improvement of 2.5 percentage points YoY [2] - Clinical research services revenue rose by 14.2% YoY and fell by 14% QoQ, with gross margin also improving by 2.5 percentage points YoY [2] - CGT revenue grew by 7.9% YoY and 2.2% QoQ, although gross margin declined significantly by 30.3 percentage points YoY due to increased operational and depreciation costs [2] Order Growth - Overall new orders in Q1 2025 achieved a growth rate of over 10% YoY, with CMC's backlog orders growing by over 20% YoY [3] - Management maintains a revenue guidance of 10%-15% growth for the full year 2025, despite a slowdown in new order growth compared to previous quarters [3] External Factors - The impact of tariffs on the company is limited, with minimal reliance on U.S. sourced materials, and the company is well-prepared with sufficient inventory [4] - The recovery of overseas biopharmaceutical financing remains slow, with only signs of moderate recovery in VC financing [4] Investment Rating - The company maintains a "Buy" rating, with target prices set at HKD 20 for Hong Kong shares and RMB 32 for A-shares, reflecting a premium of 80% for A-shares compared to Hong Kong shares [5]

Core Viewpoint - The company reported a positive performance in Q1 2025, with revenue and net profit showing significant year-on-year growth, driven by the recovery in innovative drug financing and an increase in new orders [1][2][4]. Revenue Summary - In Q1 2025, the company achieved revenue of 3.099 billion yuan, representing a year-on-year increase of 16.03% [1][2]. - Revenue breakdown by service: - Laboratory services: 1.857 billion yuan (+15.74%) - CMC services: 693 million yuan (+19.05%) - Clinical research services: 447 million yuan (+14.25%) - Large molecule and cell & gene therapy services: 99 million yuan (+7.94%) [2]. Profit Summary - The company reported a net profit attributable to shareholders of 306 million yuan in Q1 2025, reflecting a year-on-year growth of 32.54% [3]. Order and Project Delivery Summary - The company experienced a recovery in new orders, with a year-on-year increase of over 10% in Q1 2025, attributed to the resurgence in innovative drug financing [5]. - Core business is expected to grow steadily, with projected revenue growth of 10%-15% for 2025 [5]. - Specific growth in laboratory services includes a revenue increase of 15.7% and new orders growth of over 10% [5]. Investment Outlook - Projected net profits for the company from 2025 to 2027 are 1.928 billion yuan, 2.148 billion yuan, and 2.389 billion yuan, respectively [6]. - The expected EPS for 2025 is 1.08 yuan per share, with a target price of 27.00 yuan per share based on a 25x PE ratio, suggesting a "Buy-A" investment rating [6].

Core Insights - The global and US innovative drug VC&PE financing amounts are expected to grow by 1.93% and 5.29% respectively in 2024, indicating a recovery in the innovative drug financing environment [1] - The demand for research and development in fields such as peptides and ADCs is strong, leading to an increase in outsourcing needs in these areas [1][2] Macro Perspective - The global innovative drug financing environment is recovering, with significant growth in the demand for innovative research in specific fields like peptides and ADCs, which is expected to enhance the CXO industry's outlook [1] - According to Crunchbase, the VC&PE financing for innovative drugs in 2024 shows positive growth, marking an improvement in the financing environment [1] Micro Perspective - CXO listed companies are seeing a recovery in new orders, with many companies like WuXi AppTec, WuXi Biologics, and others reporting a year-on-year increase of over 20% in new orders [3] - The production capacity of domestic CXO companies is mature, ensuring timely delivery of orders, which is expected to lead to double-digit revenue growth for several companies in 2025 [3] Target Companies - Recommended companies to watch include WuXi AppTec (603259.SH, 02359), WuXi Biologics (02269), WuXi AppTec (02268), Kelun Pharmaceutical (002821.SZ, 06821), and others [4]

Financial Performance - The company's revenue for Q1 2025 reached ¥3,098,813,569.89, representing a 16.03% increase compared to ¥2,670,740,738.16 in the same period last year[6] - Net profit attributable to shareholders was ¥305,575,186.04, up 32.54% from ¥230,557,834.70 year-on-year[6] - The adjusted net profit attributable to shareholders was ¥349,441,031.17, reflecting a 3.14% increase from ¥338,816,299.13 in the previous year[6] - Total revenue for the period reached CNY 3,098,813,569.89, an increase of 15.9% compared to CNY 2,670,740,738.16 in the previous period[35] - Net profit for the period was CNY 279,654,565.09, representing a 29.5% increase from CNY 215,919,833.12 in the prior period[36] - The company reported a profit before tax of RMB 363,587,000, compared to RMB 268,619,000 in the previous year, an increase of 35.4%[42] - Total comprehensive income for the period reached RMB 389,670,737.53, compared to RMB 162,642,198.05 in the previous period, representing an increase of approximately 139.5%[37] Revenue Breakdown - Revenue from laboratory services was ¥1,857,202,616.77, a 15.74% increase from ¥1,604,576,678.01 year-on-year, with a gross margin of 45.54%[8] - Revenue from CMC (small molecule CDMO) services was ¥693,023,486.59, up 19.05% from ¥582,104,488.92, with a gross margin of 30.44%[8] - Revenue from clinical research services reached ¥447,320,929.08, a 14.25% increase from ¥391,531,326.06, with a gross margin of 11.76%[8] - Revenue from the top 20 global pharmaceutical companies was ¥455,746,000, a 29.05% increase, accounting for 14.71% of total revenue[9] Shareholder Metrics - Basic earnings per share increased by 33.54% to CNY 0.1736, reflecting the growth in net profit attributable to shareholders[14] - Diluted earnings per share rose by 33.51% to CNY 0.1733, also attributed to the increase in net profit[15] - The total number of common shareholders at the end of the reporting period was 79,841[20] - The company announced a profit distribution plan for the year 2024, which is expected to enhance shareholder value[28] Cash Flow and Assets - The company's cash flow from operating activities amounted to ¥852,829,144.27, a 14.38% increase compared to ¥745,630,586.78 in the same period last year[6] - Cash flow from investing activities resulted in a net outflow of RMB 1,212,095,238.52, worsening from a net outflow of RMB 467,094,044.67 in the previous period[40] - Cash flow from financing activities showed a net outflow of RMB 98,926,715.92, an improvement compared to a net outflow of RMB 1,512,600,594.24 last period[41] - The total current assets decreased from CNY 7,608,179,522.72 to CNY 7,384,443,685.17, representing a decline of approximately 2.95%[30] - Cash and cash equivalents decreased from CNY 1,689,916,082.15 to CNY 1,262,763,166.96, a reduction of about 25.3%[30] Expenses and Liabilities - Total operating costs amounted to CNY 2,713,717,115.43, up from CNY 2,439,362,705.75, reflecting a growth of 11.2%[35] - Research and development expenses grew by 30.56% to CNY 122,210,590.15, indicating a continued commitment to R&D investment[18] - Income tax expenses rose by 59.27% to CNY 83,932,205.84, corresponding to the increase in total profit[19] - The total liabilities decreased slightly to CNY 9,686,700,206.35 from CNY 9,704,526,037.38, a reduction of 0.2%[33] Other Financial Metrics - Other comprehensive income increased significantly by 1,370.30% to CNY 98,545,941.98, driven by foreign currency translation differences and cash flow hedging[18] - The company's total non-current assets increased to CNY 16,948,379,035.81 from CNY 16,319,218,798.51, marking a growth of 3.9%[31] - The equity attributable to the parent company increased to RMB 14,042,172 thousand from RMB 13,619,335 thousand, marking a growth of 3.1%[44] - The company's goodwill increased to RMB 2,947,429 thousand from RMB 2,760,736 thousand, reflecting a growth of 6.8%[43]

证券代码：300759 证券简称：康龙化成 公告编号：2025-026 康龙化成（北京）新药技术股份有限公司 关于非执行董事辞职暨 补选公司第三届董事会非执行董事的公告 事会任期届满之日止。 胡柏风先生在任职期间勤勉尽责，致力于公司的规范运作和健康发展，并凭 借自身积累的丰富投资经验，为公司可持续发展提供了诸多宝贵建议，公司董事 会对胡柏风先生在任职期间为公司及董事会所做出的贡献表示衷心感谢！ 特此公告。 康龙化成（北京）新药技术股份有限公司董事会 2025 年 4 月 28 日 2 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日召开第三届董事会第十四次会议，审议通过了《关于补选公司第三届董 事会非执行董事的议案》。胡柏风先生因本职工作调整，申请辞去公司第三届董 事会非执行董事及董事会战略委员会委员职务（第三届董事会原定任期至 2026 年 6 月 20 日），辞职后胡柏风先生将不再担任公司任何职务。胡柏风先生自愿继 续履行非执行董事及董事会战略委员会委员职责至公司股东 ...